NES and acute myeloid leukemia: Nestin+ BM-MSCs support survival and chemotherapy relapse of AML through increased oxidative phosphorylation, tricarboxylic acid (TCA) cycle activity, and glutathione (GSH)-mediated antioxidant defense (Forte et al., 2020) with increased GPX activity.